Skip to content

Study · Randomized controlled trial · n = 14,752 · 2023

2 results

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Green JB, Merrill P, Lokhnygina Y, Mentz RJ, Alfredsson J, Holman RR

Diabetes, obesity & metabolism14 Feb 2023Cited by 2 (Europe PMC)

PMID36700460 (opens in a new tab)DOI10.1111/dom.14993 (opens in a new tab)PepBankPUB-36700460
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, MACE3 did not differ between once-weekly exenatide and placebo.

    In plain wordsIn people with type 2 diabetes, major cardiovascular events did not differ between once-weekly exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMACE3
    Study

    n = 14,752

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no difference in MACE3 with EQW compared with placebo, or evidence of heterogeneity of treatment effect by sex.
    3 context sentences
    Summary · context
    Cox proportional hazards regression models were used for clinical outcomes, including the primary composite outcome of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke (MACE3).
    Summary · context
    Overall, 5603 women and 9149 men were followed for a median of 3.2 years.
    Summary · context
    To examine sex differences in the characteristics and outcomes in participants with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), randomized to once-weekly exenatide (EQW) or placebo in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with type 2 diabetes, the exenatide effect on MACE3 versus placebo showed no evidence of heterogeneity by sex.

    In plain wordsIn people with type 2 diabetes, exenatide's cardiovascular effect versus placebo showed no evidence of a difference by sex.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSex heterogeneity of MACE3 treatment effect
    Study

    n = 14,752

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no difference in MACE3 with EQW compared with placebo, or evidence of heterogeneity of treatment effect by sex.
    2 context sentences
    Summary · context
    Overall, 5603 women and 9149 men were followed for a median of 3.2 years.
    Summary · context
    To examine sex differences in the characteristics and outcomes in participants with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), randomized to once-weekly exenatide (EQW) or placebo in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.